Polyphor AG bags CHF19.3 in equity financing
Swiss Polyphor AG has strengthened its financial flexibility with an equity-linked financing.
COVID-19: Siemens assay outperforms antibody tests from competitors
In a Public England Health study, Siemens Healthineers COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA.
AMR: Big Pharma sets up US$1bn Fund
After leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance (AMR).
VarmX bags 32m in Series B round
Leiden-based coagulant developer VarmX NV has closed a 32m Series B financing to push the Phase II development of VMX-C001, a venom-based modified recombinant Factor X.
APEIRON Biologics licences MaxCytes electroporation platform
Viennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcytes electroporation platform for APN401 development.
Immatics launches US$250m Nasdaq-IPO
After closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq.
New insulin formulation allows faster blood sugar management
A new insulin formulation allows patients with diabetes to more quickly manage their blood sugar levels during mealtimes.
COVID-19: Lopinavir-ritonavir failed
Data from the UKs RECOVERY trial demonstrate there was no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients.
EC pledges 4.9bn to grant access to medicines
Under the Coronavirus Global Response Framework, the European Commission is allocating further 4.9bn to assure access to COVID-19 countermeasures for poor countries.
BioGeneration Ventures closes BGV IV Fund at 105m
BioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at 105m.